Carving-In Innovation: Payment Reform and Biopharma
This article was originally published in RPM Report
Executive Summary
When it comes to health care reform, Democrats and Republicans don’t appear to agree on very much. But during a BIO annual meeting session, three key policymakers representing both sides of the aisle in the Senate and the Obama Administration did agree on one thing: it is time for industry to stop asking to be “carved out” of new payment systems, and to start proving the value of its products.
You may also be interested in...
Biopharma's Default Position: Drug Stocks Hold Up Against US Downgrade
Economists are fretting that the US may be heading into a “lost decade” of stagnation. Will those fears help Big Pharma investors finally end a lost decade of their own?
FDA and the R&D Crisis: Time to Stop the Blame Game
Everyone knows R&D productivity has dipped to levels that threaten the private drug development model, and almost everyone says regulatory hurdles are part of the problem. That isn’t how FDA sees it. One thing is clear: blaming FDA won’t help anyone, so it may be time to pay more attention to FDA’s ideas for solutions rather than continue to point fingers.
Teenage Wasteland: Paying for New Drugs and Other "Adolescent" Technologies
The debate over comparative effectiveness research has focused heavily on standards of evidence to judge the relative value of different therapies and standards for when and how conclusions should drive coverage policy. Less attention has been paid to a more fundamental question: when should the value determination be made. CMS’ top coverage official has an idea that would radically change that process.